$1.64
3.53% today
Nasdaq, Feb 28, 04:44 pm CET
ISIN
US6033801068
Symbol
NERV
Sector
Industry

Minerva Neurosciences Inc Stock price

$1.70
-0.67 28.27% 1M
-1.07 38.63% 6M
-0.52 23.48% YTD
-1.10 39.29% 1Y
-3.95 69.91% 3Y
-55.74 97.04% 5Y
-39.42 95.87% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.05 2.86%
ISIN
US6033801068
Symbol
NERV
Sector
Industry

Key metrics

Market capitalization $11.89m
Enterprise Value $50.43m
P/E (TTM) P/E ratio 8.94
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-21.85m
Free Cash Flow (TTM) Free Cash Flow $-19.55m
Cash position $21.46m
EPS (TTM) EPS $0.19
Short interest 0.50%
Show more

Is Minerva Neurosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Minerva Neurosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Minerva Neurosciences Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Minerva Neurosciences Inc:

Hold
100%

Financial data from Minerva Neurosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.02 0.02
33% 33%
-
-0.02 -0.02
33% 33%
-
- Selling and Administrative Expenses 9.90 9.90
4% 4%
-
- Research and Development Expense 12 12
6% 6%
-
-22 -22
5% 5%
-
- Depreciation and Amortization 0.02 0.02
33% 33%
-
EBIT (Operating Income) EBIT -22 -22
5% 5%
-
Net Profit 1.44 1.44
105% 105%
-

In millions USD.

Don't miss a Thing! We will send you all news about Minerva Neurosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Minerva Neurosciences Inc Stock News

Neutral
GlobeNewsWire
3 days ago
BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2024.
Neutral
GlobeNewsWire
4 months ago
BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2024 ending September 30, 2024.

Company Profile

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.

Head office United States
CEO Rémy Luthringer
Employees 8
Founded 2007
Website www.minervaneurosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today